Publications
1,118
Citations
25,834
Est. group size
~48
Recurring co-author estimate
Active years
28
Publishing since 1999
Typically publishes in teams of ~15 · 7% small-team papers (≤3 authors) · across 71 venues
- A phase 1 study of PHST001, an anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors.
Journal of Clinical Oncology · 2026
- Supplementary Data 1 from Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169
2026
- Supplementary Figures1 from Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169
2026
- Supplementary Tables1 from Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169
2026
- Data from Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169
2026
- Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors.
PubMed · 2025
- A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
ESMO Open · 2025
- Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors
Journal of Kidney Cancer and VHL · 2025
- Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial
Journal for ImmunoTherapy of Cancer · 2025
- COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Journal of Clinical Oncology · 2025
- Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma
Journal of Kidney Cancer and VHL · 2025
- Cabozantinib (C) ± atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Expansion cohorts from the open-label phase 1b COSMIC-021 study.
Journal of Clinical Oncology · 2025
- Burden of cancer in metastatic renal cell carcinoma (mRCC).
Journal of Clinical Oncology · 2025
- Supplementary Table S1 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025
- Supplementary Table S3 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025
- Journal of Clinical Oncology×181
- Annals of Oncology×45
- Clinical Cancer Research×13
- Clinical Genitourinary Cancer×13
- The Oncologist×12
- Toni K. Choueiri
Medicine · University of Michigan
- Megan Hinkley
Medicine · The Ohio State University
- Taylor Goodstein
Medicine · The Ohio State University
- Elshad Hasanov
Medicine · The Ohio State University
- Theodore F. Logan
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile